E-4031 induces dose-dependent QT prolongation and torsade de pointes in chronic AV block dogs, providing a bridge between in vitro proarrhythmia assays and clinical observations.
Answers are grounded in this paper and cite their sources.
May guide preclinical torsades screening; leaves open human translation without clinical validation.
We analyzed torsadogenic and pharmacokinetic profile of E-4031 using chronic atrioventricular block dogs. E-4031 in intravenous doses of 0.03, 0.1 and 0.3 mg/kg over 10 min prolonged QT/QTc, and increased short-term variability of QT in a dose-related manner (n = 4), resulting in onset of torsade de pointes in 1 animal after the middle dose and 4 animals after the high dose, while it attained peak plasma concentrations of 16.5, 60.5 and 182.5 ng/mL at 10 min after their start of administration, respectively (n = 2). These results bridge the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: